News

The Mission Thrombectomy 2020+ group outlined a plan to increase the awareness, accessibility, and action for mechanical thrombectomy utilization for patients with stroke globally.

The drug joins Cerebryx as the second FDA-approved fosphenytoin for benzodiazepine-refractory status epilepticus.

New recommendations were developed for the use of rituximab, eculizumab, and methotrexate, as well as updates on previous recommendations for thymectomy.

The director of Translational Research and Clinical Trials Epilepsy at NYU Grossman School of Medicine discussed the groundwork done with the Human Epilepsy Project for a recent analysis.

An analysis from English and Scottish stroke centers provides physicians a new view of the trends and outcomes of patients with COVID-19 who experience stroke.

The Cleveland Clinic researcher discussed the unknowns about Parkinson disease dementia and what has been previously observed in clinical studies.

Here's what is coming soon to NeurologyLive.

A tertiary analysis of the AVERT study reveals divergent findings suggesting that mortality increases with VEM compared to usual care after restricting follow-up to 14 days.

The associate professor of neurology at Washington University in St. Louis detailed a number of key presentations on advances and novel medications in the sleep space.

The research coordinator of the Dravet Foundation provided background on the new ICD-10 codes announced for Dravet syndrome and how they came about.

There is no evidence yet that SARS-CoV-2 can pass the blood-brain barrier, though its effects on the barrier may be intensified in those with dementia.

Neurology News Network for the week ending November 7, 2020.

Biogen’s investigational Alzheimer disease treatment is currently under review with a Prescription Drug User Fee Act target action date of March 7, 2021, if not earlier.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 6, 2020.

The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, described the challenges he’s faced when having to discuss a change in treatment strategies with his patients.

The decision was based on findings from the phase 3 THALES trial, which showed aspirin plus ticagrelor significantly reduced stroke and death compared with aspirin alone in patients with acute ischemic stroke or TIA.

Based on data from a study of 686 patients with subjective cognitive impairment or dementia, the PrecivityAD blood test correctly identified brain amyloid plaque status in 86% of the patients.